NHS England has made Roche’s emicizumab (also referred to as Hemlibra®) available on NHS and is set to fund the “life-changing treatment” for thousands of people with severe Haemophilia. A move which is said to dramatically cut patient’s risk of life-threatening bleeds and reduce treatment time. The new treatment is part of a package of
The MS Society has begun a petition calling for NICE, NHS England and drug manufacturer, Roche, to rethink NICE’s decision to reject the first treatment to be licensed for the treatment of primary progressive multiple sclerosis (PPMS). NICE announced in September that it would not be making ocrelizumab for PPMS available on the NHS in
It is starting to look highly unlikely that patients with giant cell arteritis will gain NHS access to Roche’s Roactemra, due to the drug being turned down by cost regulators in draft guidelines. NICE’s appraisal committee has emphasised “substantial uncertainties” in the evidence on how long patients would have to take the treatment and what
NHS England and Roche have confirmed a confidential commercial agreement on the price of Perjeta for certain patients with breast cancer. NHS England has stated that the agreement will allow NICE to carry out the final stage of its appraisal for the drug “and opens the way for continued access to this important treatment for
Roche’s Alecensa has shown strong results in two studies looking at its benefits in ALK positive non-small cell lung cancer (NSCLC) patients, both in first line use and a second line setting. Alecensa is directly competing against the established drug for ALK+ lung cancer, Pfizer’s Xalkori, and has already proved itself to be superior in
Roche’s Tecentriq has scored another positive opinion. The Medicines and Healthcare products Regulatory Agency (MHRA) has recently accepted the immunotherapy drug into the Early Access to Medicines Scheme (EAMS) for the treatment advanced bladder cancer. The decision means that patients suffering from bladder cancer could have access to the drug while it awaits decision from
Roche has today announced that they have acquired Germany’s Signature Diagnostics. Signature Diagnostics were a privately-held translational oncology and genomics company, based in Potsdam, Germany. The acquisition is the fifth deal that Roche has made within the past year, aimed at building their molecular diagnosis business. Signature Diagnostics focuses on developing large blood plasma and
Roche have today announced their 2014 results, with sales in 2014 growing 1% (5% at constant exchange rates) to 47.46 billion francs. However, net profit for the healthcare company fell 16% to 9.54 billion francs, hit by a one-time restructuring charge. Sales increased 4% (at constant exchange rates) in the Pharmaceuticals Division to 36.7 billion
Roche has announced positive Q3 results for 2014, with pharmaceutical sales increasing by 4% in the third quarter to 9.13bn francs, while their diagnostics division grew by 7% to 2.65bn francs. The results were boosted by increased sales of Roche’s new breast cancer drugs, Perjeta and Kadcyla. Sales of Perjeta more than tripled to reach
Roche have revealed positive financial results for the third quarter, strengthened by the sustained growth of their cancer drugs. Earlier today Roche announced that sales reached 11.57 billion Swiss francs, an increase of 8%, while their pharmaceutical revenue grew by 9% to 9.03 billion Swiss francs. Roche’s best-selling drug was MabThera/Rituxan (rituximab), which has been
